Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 37, 327-328, January 1, 1977]
© 1977 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertino, J. R.
Right arrow Articles by Gupta, V. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertino, J. R.
Right arrow Articles by Gupta, V. S.

Schedule-dependent Antitumor Effects of Methotrexate and 5-Fluorouracil1

J. R. Bertino2, W. L. Sawicki, C. A. Lindquist and V. S. Gupta3

Department of Pharmacology [J. R. B., C. A. L.] and Medicine [J. R. B., W. L. S., V. S. G.], Yale University School of Medicine, New Haven, Connecticut 06510

The antitumor effects of methotrexate with 5-fluorouracil against the Sarcoma 180 mouse tumor model were found to be schedule dependent. Pretreatment of tumor-bearing animals with methotrexate significantly enhanced the antitumor activity of the combination relative to simultaneous treatment or to those with methotrexate following 5-fluorouracil. These studies indirectly support the hypothesis that methotrexate pretreatment with 5-fluorouracil is synergistic by increasing the amount of thymidylate synthetase bound to the active metabolite of 5-fluorouracil.

1 Supported by Grants CA-08010 and CA-08341 from the USPHS.

2 American Cancer Society Research Professor.

3 Visiting Professor, Yale University School of Medicine. Present address: Department of Physiological Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

Received 11/11/75. Accepted 10/ 5/76.




This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
B. Fisher, J.-H. Jeong, S. Anderson, and N. Wolmark
Treatment of Axillary Lymph Node-Negative, Estrogen Receptor-Negative Breast Cancer: Updated Findings From National Surgical Adjuvant Breast and Bowel Project Clinical Trials
J Natl Cancer Inst, December 15, 2004; 96(24): 1823 - 1831.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
E Cadman, R Heimer, and L Davis
Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism
Science, September 14, 1979; 205(4411): 1135 - 1137.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1977 by the American Association for Cancer Research.